论文部分内容阅读
最近,美国医生们在研究一种治疗严重血液病以减少患者输血次数的药物时意外发现,其中近一半患者的病症消失。专家们说,目前处实验阶段的药物Revlimid看来是一个突破,是治疗骨髓增生异常综合征(MDS)的第一种有效治疗药物。范德比尔特大学英格伦癌症中心的DavidJohnson博士说,即使这种药物不能根除骨髓增生异常综合征,但也能大大减轻病症。DavidJohnson博士还说,Revlimid尚未投入市场,但鉴于这些研究结果,它以后肯定会在市场上出现。
Recently, when doctors in the United States discovered a drug that was designed to treat severe blood diseases to reduce the number of blood transfusions in patients, nearly half of them disappeared. Experts say Revlimid, the current experimental phase of the drug, appears to be a breakthrough and is the first effective treatment for myelodysplastic syndrome (MDS). Dr. David Johnson of Vanderbilt University Ingrid Cancer Center said that even though the drug does not eradicate myelodysplastic syndromes, it can greatly reduce the symptoms. Dr. David Johnson also said that Revlimid has not yet been put on the market, but given the results of these studies, it will certainly appear in the market later.